| Prev Close | 96.88 |
| Open | 96.94 |
| Day Low/High | 96.55 / 97.52 |
| 52 Wk Low/High | 69.18 / 99.84 |
| Volume | 2.54M |
| Avg Volume | 1.84M |
Novartis AG (NVS)
96.90
0.02
0.02
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.47B |
| Market Cap | 217.73B |
| EPS | 3.10 |
| P/E Ratio | 30.85 |
| Div & Yield | 2.01 (2.29%) |
Latest News
Looks That Kill a Rally? Bad Breadth, More Relief, Rockin' and Trading Silver
Monday's rally might have been ugly, except that this is 2020. Anything goes in 2020.
I'm Adding This Pharma Company to My Top Stocks for 2020 List
Recro Pharma Inc., which makes drugs such as Ritalin LA for Novartis, looks healthy going into 2020.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Big Merger Monday Conjures Up Thoughts of Potential Biotech Targets
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
Jim Cramer: Here's Why the Market Hasn't Stopped Rallying
These are the 10 reasons why we keep going up, despite all the bad news.
Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not
We're seeing lots of companies snapping up their peers, and the market is applauding.
Novartis Is Moving Higher on the Charts, Go Long or Add to Longs
Let's check in on this Swiss-based pharmaceutical giant.
Jim Cramer: Here's the Good News About the U.S./China Trade Delay
There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Jim Cramer: Here's How to Look at Stocks in Earnings Season
On the biggest day for earnings reports in the S&P let me give you my scorecard to date so you know which pile your stocks might land in.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
For Wealth and Safety Invest With a 'Shark'
Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.
Charts of Alcon Look Good
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.
It's Tough to Weed Through the Data on Tilray
The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.
Tilray Stock Gains Ahead of Highly Anticipated Earnings Release
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Should You Go for the 'Easy Money' in Novartis?
NVS been in an uptrend the past twelve months.
Jim Cramer: Looking for Netflix Action? Don't Be a Hero
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
Market Yin and Yang
We've got some push-pull in pre-market trading as moves lower in Netflix , Limelight Networks , United Rentals , SAP and Alcoa duel with Apple , which is moving higher pre-market, and positive moves in Novartis , eBay , Phillip Morris International ...
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point
Let's review the charts and indicators this morning.
Jim Cramer: The Forbidden City of Stock Sectors
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
